BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Alembic Pharmaceuticals Ltd. Share Price

NSE
BSE

NSE : APLLTD

BSE : 533573

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹762.15

High

₹779.15

Price Summary

Previous Close ₹767.85
Day's Range ₹762.15 - ₹779.15
Open ₹768.15
52 Week Range ₹635.80 - ₹1,107.90
Volume 36,866
Market Cap ₹0.02
Previous Close ₹770.95
Day's Range ₹763.20 - ₹780.00
Open ₹775.95
52 Week Range ₹635.30 - ₹1,107.80
Volume 3,647
Market Cap ₹0.02

Stocks Summary

Trade Value ( ₹ in Lacs) 283.08
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 1.43
Price/Earning (TTM) 24.01
TTM EPS (₹) 32.00
P/E Ratio 31.31
Book Value(₹) 2.77
PAT Margin (%) 8.72
Face Value (₹) 2.00
ROCE(%) 13.51
Trade Value ( ₹ in Lacs) 28.12
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 1.43
Price/Earning (TTM) 24.01
TTM EPS (₹) 32.00
P/E Ratio 31.31
Book Value(₹) 2.77
PAT Margin (%) 8.72
Face Value (₹) 2.00
ROCE(%) 13.51

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 14060.9 62286.3
Expenses N/A N/A
PBT 1038.1 6318.2
Operating profit 0.0 0.0
Net profit 858.1 6158.2

Shareholding Pattern

Promoters (% Holding)

69.74%

Mutual funds (% Holding)

8.18%

Non-Institution (% Holding)

9.83%

FI/Banks/Insurance (% Holding)

7.71%

Government (% Holding)

0.00%

FII

4.26%

About Alembic Pharmaceuticals Ltd.

Founded 2010
Managing Director Shaunak Amin
NSE Symbol APLLTD

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,37,734.67 1,824.40 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,80,311.57 6,789.10 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,45,369.09 4,325.20 3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd. 1,15,044.98 8,008.45 6,696.50 - 6,696.50
Cipla Ltd. 1,07,204.87 1,330.35 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,05,592.45 1,265.10 1,148.40 - 1,148.40
Lupin Ltd. 1,01,293.89 2,215.45 1,836.80 - 1,836.80
Max Healthcare Institute Ltd. 99,791.55 1,025.35 903.00 - 903.00
Mankind Pharma Ltd. 99,384.29 2,415.30 1,909.70 - 1,909.70
Zydus Lifesciences Ltd. 94,480.34 940.00 835.50 - 835.50
no-content No Records Found

Latest News

Apr
27
2026
EQUITY Posted on Apr 27th 2026

Alembic Pharmaceuticals informs about demise of senior management personnel

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Alembic Pharmaceuticals has informed about the sad demise of Saibal Mukherjee, Resident Director (Delhi Office) of the Company on 26th April, 2026. Saibal Mukherjee joined the Company in 2014 and had been an integral part of the organisation. His sudden and unexpected demise will be an irreparable loss to the Company and all the directors and employees of the Company convey deep sympathy, sorrow and condolences to his family. The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January 2026 is attached as Annexure-A.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
23
2026
EQUITY Posted on Apr 23rd 2026

Alembic Pharmaceuticals informs about incorporation of wholly-owned subsidiary company

Alembic Pharmaceuticals has informed that the Company has incorporated a wholly owned subsidiary named Alembic Pharmaceuticals GmbH in Germany. The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid incorporation is enclosed as Annexure - I.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
17
2026
EQUITY Posted on Apr 17th 2026

Alembic Pharmaceuticals informs about newspaper advertisement

Alembic Pharmaceuticals has informed that it enclosed paper cuttings of newspaper advertisement issued regarding a Second 100-Day Campaign, launched by Investor Education and Protection Fund Authority (IEPFA) and Ministry of Corporate Affairs (MCA), titled as ‘Saksham Niveshak’ to facilitate Dividend claims and KYC updates published in Indian Express (English Edition) and Financial Express (Gujarati Edition - vernacular language) on 17th April, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
16
2026
EQUITY Posted on Apr 16th 2026

Alembic Pharmaceuticals informs about media release

Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Methotrexate Injection USP, 50 mg/2 mL (25 mg/mL) Multi-Dose Vials & 1g/40 mL (25 mg/mL) Single-Dose Vials.
The above information is a part of company’s filings submitted to BSE. 
Read More
Apr
1
2026
EQUITY Posted on Apr 1st 2026

Alembic Pharmaceuticals informs about appointment of non-executive non-independent director

Alembic Pharmaceuticals has informed that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors, the Shareholders of the Company vide Postal Ballot dated 31st March, 2026, approved the appointment of Rajkumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director, liable to retire by rotation with effect from 1st April, 2026. In this regard, the company has declared that Rajkumar Baheti is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 is attached as ‘Annexure-A’.

The above information is a part of company’s filings submitted to BSE.

Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Alembic Pharmaceuticals Ltd. ?

The current share price of Alembic Pharmaceuticals Ltd. is ₹767.85 as of 2026-05-13.

The market capitalisation of Alembic Pharmaceuticals Ltd. is ₹15,103.91 as of 2026-05-13.

The 1-year return of Alembic Pharmaceuticals Ltd. is 0.00% as of 2026-05-13.

The P/E ratio of Alembic Pharmaceuticals Ltd. is 31.31 as of 2026-05-13.

The 52-week high and low of Alembic Pharmaceuticals Ltd. are ₹1,107.90 and ₹635.80, respectively, as of 2026-05-13.

The dividend yield of Alembic Pharmaceuticals Ltd. is 1.4315% as of2026-05-13.

You can buy Alembic Pharmaceuticals Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Alembic Pharmaceuticals Ltd. is Shaunak Amin.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore